IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 35M 70M 105M Q3 '24: 58.6M Q4 '24: 73.7M Q1 '25: 49.3M Q2 '25: 60M Q3 '25: 67.5M Q4 '25: 86.8M Q1 '26: 71.4M Q2 '26: 99.3M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

0 20M 40M 60M Q3 '24: 27M Q4 '24: 35.9M Q1 '25: 6.6M Q2 '25: 11.1M Q3 '25: 29M Q4 '25: 43.7M Q1 '26: 28.9M Q2 '26: 55.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '24: -89.1M Q4 '24: -86.6M Q1 '25: -121.2M Q2 '25: -113.8M Q3 '25: -94.9M Q4 '25: -73.5M Q1 '26: -81M Q2 '26: -51.9M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income Quarterly

-120M -80M -40M 0 40M 80M 120M Q3 '24: -83.5M Q4 '24: -78.6M Q1 '25: -116.2M Q2 '25: -111.7M Q3 '25: -91.3M Q4 '25: -71.9M Q1 '26: -79M Q2 '26: -47.3M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

0 20M 40M 60M Q3 '24: 31.5M Q4 '24: 37.8M Q1 '25: 42.7M Q2 '25: 48.9M Q3 '25: 38.5M Q4 '25: 43.1M Q1 '26: 42.5M Q2 '26: 43.6M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow Quarterly

-120M -80M -40M 0 40M 80M 120M Q3 '24: -59M Q4 '24: -73.3M Q1 '25: -103.7M Q2 '25: -67.4M Q3 '25: -78.7M Q4 '25: -52.6M Q1 '26: -72.1M Q2 '26: -60.8M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-120M -80M -40M 0 40M 80M 120M Q3 '24: -61.3M Q4 '24: -77.5M Q1 '25: -109.9M Q2 '25: -74.9M Q3 '25: -89.5M Q4 '25: -61.9M Q1 '26: -78.7M Q2 '26: -66.3M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 200K 400K 600K Q1 '24: 266.2K Q2 '24: 284.8K Q3 '24: 303.3K Q1 '25: 322.9K Q2 '25: 334.5K Q3 '25: 364K Q1 '26: 418.5K Q2 '26: 450.2K Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.70 -1.80 -0.90 0.00 0.90 1.80 2.70 Q4 '19: -1.58 Q1 '20: -1.83 Q2 '20: -1.92 Q1 '22: -2.29 Q2 '22: -2.39 Q3 '22: -2.47 Q4 '22: -2.48 Q1 '23: -2.40 Q4 '19 Q1 '20 Q2 '20 Q1 '22 Q2 '22 Q3 '22 Q4 '22 Q1 '23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.